Phase 1 MPR Clinical Trials
15 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–15 of 15 trials
Recruiting
Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Hematopoietic and Lymphoid Cell NeoplasmImmunocompromised
M.D. Anderson Cancer Center16 enrolled1 locationNCT03425526
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 1,1-Dimethyl-2-Phenylethylamine 40 mg capsule against the innovator 1,1-Dimethyl-2-Phenylethylamine 40 mg capsule conducted under fasting condition and at steady state in healthy male and female volunteers.
1,1-Dimethyl-2-Phenylethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12618000563268
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 1,1-Dimethyl-2-Phenylethylamine 15 mg capsule against the innovator 1,1-Dimethyl-2-Phenylethylamine 15 mg capsule conducted under fasting condition in healthy male and female volunteers.
1,1-Dimethyl-2-Phenylethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12618000423213
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 1,1-Dimethyl-2-Phenylethylamine capsule against the innovator 1,1-Dimethyl-2-Phenylethylamine capsule conducted under fasting condition in healthy male and female volunteers.
1,1-Dimethyl-2-Phenylethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12618000308291
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 1,1-Dimethyl-2-Phenylethylamine capsule against the innovator 1,1-Dimethyl-2-Phenylethylamine capsule conducted under fed condition in healthy male and female volunteers.
1,1-Dimethyl-2-Phenylethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction
Zenith Technology Corporation Limited20 enrolled1 locationACTRN12617001555347
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 15 mg alpha,alpha-dimethylphenethylamine tablet against the innovator 15 mg alpha,alpha-dimethylphenethylamine capsule conducted under fasting conditions in healthy male and female volunteers.
alpha,alpha-dimethylphenethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction.
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12617001384347
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of alpha,alpha-dimethylphenethylamine tablet against the innovator alpha,alpha-dimethylphenethylamine capsule conducted under fasting conditions and at steady state in healthy male and female volunteers.
alpha,alpha-dimethylphenethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction.
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12617001321336
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of alpha,alpha-dimethylphenethylamine tablet against the innovator alpha,alpha-dimethylphenethylamine capsule conducted under fed conditions in healthy male and female volunteers.
alpha,alpha-dimethylphenethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction.
Zenith Technology Corp Ltd24 enrolled1 locationACTRN12617001314314
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of alpha,alpha-dimethylphenethylamine tablet against the innovator alpha,alpha-dimethylphenethylamine capsule conducted under fasting conditions in healthy male and female volunteers.
alpha,alpha-dimethylphenethylamine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction.
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12617001303336
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of 2-methyl-1-phenylpropan-2-amine (122-09-8) capsule against the innovator 2-methyl-1-phenylpropan-2-amine (122-09-8) capsule conducted under fed condition in healthy male and female volunteers.
2-methyl-1-phenylpropan-2-amine (122-09-8) is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction
Zenith Technology Corporation Limited24 enrolled1 locationACTRN12617001093370
Completed
Phase 1
Comparative assessment of the absorption of a generic formulation of phentermine capsule against the innovator phentermine capsule conducted under fed conditions in healthy male and female volunteers in a pilot study
Bioequivalence pilot study conducted in healthy volunteers comparing two formulations of phentermine with no health condition or problem studied.
Although this study is being conducted in healthy volunteers who are not being treated for the condition to which the medicine is used, phentermine is a C5 Controlled Drug indicated in the management of obesity as a short-term adjunct in a medically monitored comprehensive regime of weight reduction.
Zenith Technology Corp Ltd10 enrolled1 locationACTRN12617000172303
Completed
Phase 1
A Phase I, Randomised, Open Label Study of the Safety, Tolerability and Pharmacokinetics of Single Sublingual or Oral Dose of GDN-1 in Adult Healthy Volunteers.
This trial is to assess the tolerability and pharmacokinetics in healthy adult volunteers and does not focus on any particular health condition or problem.
Subsequent studies are planned to evaluate efficacy in promoting improved exercise endurance and recovery, reduced muscle damage and soreness post exercise and for its lipid lowering effects in appropriate populations.
Gordagen Pharmaceuticals Pty Ltd60 enrolled1 locationACTRN12615000560594
Not Yet Recruiting
Phase 1
Influence of Omega 3 fatty acids on osmosensation and thirst signaling
Improving thirst sensation by supplementation of Omega 3 fatty acidsFluid intakeImproving dehydration in elderly by supplementation of Omega 3 fatty acids+1 more
Victoria University, Melbourne40 enrolled1 locationACTRN12610000398000
Completed
Phase 1
Comprehension of medicine label instructions - a pilot study in glaucoma patients.
Glaucoma, medication recall, comprehension of medication instructions, compliance to treatment, visual function, severity of disease.
Catherine Rokhahr, Pharmacy, Royal Victorian Eye and Ear Hospital.200 enrolled1 locationACTRN12607000248460
Recruiting
Phase 1
Feasibility Clinical Study of the Ovalis, Inc. Patent Foramen Ovale (PFO) Closure System in Patients with Cryptogenic Neurologic Events, Migraines, and Decompression Illness
Patients with cryptogenic neurologic events, migraines and decompression illness due to patent foramen ovale
Robust Industries30 enrolled1 locationACTRN12606000407594